Insider Trading activities of Regulus Therapeutics Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regulus Therapeutics Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regulus Therapeutics Inc. since year 2005. Table 2 shows the detailed insider transactions of Regulus Therapeutics Inc. since 2005. The reporting company's ticker symbol is RGLS. The reporting company's CIK number is 1505512.
The total value of stock buying since 2005 is $22,433,193.
The total value of stock sales since 2005 is $74,021,509.
The total value of stock option exercises since 2005 is $653,174.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Regulus Therapeutics Inc. (RGLS).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-07 1,824,175 $1,659,996 0 $0 0 $0
2017-03 500,000 $607,900 0 $0 0 $0
2016-03 10,000 $71,900 0 $0 0 $0
2015-08 10,000 $76,410 0 $0 50,677 $80,728
2015-07 100,000 $1,016,995 343,133 $3,636,144 0 $0
2015-06 0 $0 13,248 $143,012 0 $0
2015-04 0 $0 220,000 $3,782,621 220,000 $171,599
2015-03 0 $0 89,230 $1,823,771 89,230 $33,907
2015-02 0 $0 2,470 $48,805 2,470 $938
2015-01 0 $0 228,300 $4,172,700 148,300 $56,354
2014-12 0 $0 0 $0 150,000 $57,000
2014-11 0 $0 3,281,911 $54,439,289 2,500 $4,350
2014-10 0 $0 301,578 $3,778,414 10,510 $11,880
2014-09 0 $0 77,300 $569,061 6,500 $8,182
2014-08 0 $0 69,810 $480,815 7,010 $2,662
2014-07 0 $0 73,705 $512,924 6,005 $5,681
2014-06 0 $0 23,705 $185,051 8,505 $10,031
2014-05 0 $0 3,505 $24,536 3,505 $1,331
2014-04 0 $0 2,500 $20,272 2,500 $4,350
2014-03 0 $0 13,015 $121,451 13,015 $8,343
2014-02 1,303,780 $9,999,992 21,005 $176,140 51,005 $83,981
2014-01 0 $0 13,505 $106,503 13,505 $24,857
2013-02 0 $0 0 $0 50,000 $87,000
2012-10 2,250,000 $9,000,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Regulus Therapeutics Inc. insiders (RGLS)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-07-25 Chevallard Daniel R. (Chief Financial Officer) Buy 54,945 .91 49,999
2017-07-25 Wright Timothy Michael (Chief R & D Officer) Buy 274,725 .91 249,999
2017-07-25 Hagan Joseph P (President and CEO) Buy 219,780 .91 199,999
2017-07-25 Rastetter William H (Director) Buy 274,725 .91 249,999
2017-07-25 Papadopoulos Stelios (Director) Buy 1,000,000 .91 910,000
2017-03-22 Papadopoulos Stelios (Director) Buy 300,000 1.23 368,100
2017-03-21 Papadopoulos Stelios (Director) Buy 200,000 1.20 239,800
2016-03-03 Hagan Joseph P (Chief Operating Officer) Buy 10,000 7.19 71,900
2015-08-13 Foletta Mark G (Director) Buy 10,000 7.64 76,410
2015-08-07 Papadopoulos Stelios (Director) Option Ex 50,677 1.59 80,728
2015-07-21 Rastetter William H (Director) Buy 61,235 10.19 624,229
2015-07-20 Rastetter William H (Director) Buy 38,765 10.13 392,766
2015-07-17 Isis Pharmaceuticals Inc (10% Owner) Sale 111,000 10.21 1,133,754
2015-07-16 Isis Pharmaceuticals Inc (10% Owner) Sale 167,000 10.79 1,801,429
2015-07-15 Isis Pharmaceuticals Inc (10% Owner) Sale 65,133 10.76 700,961
2015-06-30 Isis Pharmaceuticals Inc (10% Owner) Sale 13,248 10.79 143,012
2015-04-21 Xanthopoulos Kleanthis G (President and CEO) Sale 60,000 17.73 1,063,980
2015-04-21 Xanthopoulos Kleanthis G (President and CEO) Option Ex 60,000 .38 22,800
2015-04-20 Xanthopoulos Kleanthis G (President and CEO) Sale 66,071 16.85 1,113,494
2015-04-20 Xanthopoulos Kleanthis G (President and CEO) Option Ex 66,071 .38 25,106
2015-04-17 Xanthopoulos Kleanthis G (President and CEO) Sale 73,929 16.93 1,251,987
2015-04-17 Xanthopoulos Kleanthis G (President and CEO) Option Ex 73,929 .38 28,093
2015-04-13 Carter Bruce L A (Director) Sale 20,000 17.66 353,160
2015-04-13 Carter Bruce L A (Director) Option Ex 20,000 4.78 95,600
2015-03-05 Xanthopoulos Kleanthis G (President and CEO) Sale 89,230 20.44 1,823,771
2015-03-05 Xanthopoulos Kleanthis G (President and CEO) Option Ex 89,230 .38 33,907
2015-02-27 Xanthopoulos Kleanthis G (President and CEO) Sale 70 19.50 1,365
2015-02-27 Xanthopoulos Kleanthis G (President and CEO) Option Ex 70 .38 26
2015-02-02 Xanthopoulos Kleanthis G (President and CEO) Sale 2,400 19.77 47,440
2015-02-02 Xanthopoulos Kleanthis G (President and CEO) Option Ex 2,400 .38 912
2015-01-30 Xanthopoulos Kleanthis G (President and CEO) Sale 3,300 19.50 64,350
2015-01-30 Xanthopoulos Kleanthis G (President and CEO) Option Ex 3,300 .38 1,254
2015-01-29 Xanthopoulos Kleanthis G (President and CEO) Sale 60,000 18.08 1,085,040
2015-01-29 Xanthopoulos Kleanthis G (President and CEO) Option Ex 60,000 .38 22,800
2015-01-28 Gibson Neil W (Chief Scientific Officer) Sale 80,000 18.32 1,465,600
2015-01-28 Xanthopoulos Kleanthis G (President and CEO) Sale 85,000 18.33 1,557,710
2015-01-28 Xanthopoulos Kleanthis G (President and CEO) Option Ex 85,000 .38 32,300
2014-12-12 Papadopoulos Stelios (Director) Option Ex 150,000 .38 57,000
2014-11-28 Gibson Neil W (Chief Scientific Officer) Sale 2,500 19.21 48,037
2014-11-28 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-11-12 Astrazeneca Ab (10% Owner) Sale 2,000,000 17.00 34,000,000
2014-11-03 Parshall B Lynne (Director) Sale 1,279,411 15.94 20,391,252
2014-10-29 Gibson Neil W (Chief Scientific Officer) Sale 2,500 19.59 48,967
2014-10-29 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-10-29 Xanthopoulos Kleanthis G (President and CEO) Sale 3,505 19.62 68,757
2014-10-29 Xanthopoulos Kleanthis G (President and CEO) Option Ex 3,505 .38 1,331
2014-10-24 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,850 15.19 28,108
2014-10-24 Parshall B Lynne (Director) Sale 1,850 15.19 28,108
2014-10-23 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,700 14.24 24,202
2014-10-23 Parshall B Lynne (Director) Sale 1,700 14.24 24,202
2014-10-22 Gibson Neil W (Chief Scientific Officer) Sale 3,300 14.44 47,645
2014-10-22 Gibson Neil W (Chief Scientific Officer) Option Ex 3,300 1.74 5,742
2014-10-22 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 109,534 14.00 1,533,147
2014-10-22 Parshall B Lynne (Director) Sale 109,534 14.00 1,533,147
2014-10-20 Xanthopoulos Kleanthis G (President and CEO) Sale 300 7.00 2,100
2014-10-20 Xanthopoulos Kleanthis G (President and CEO) Option Ex 300 .38 114
2014-10-17 Xanthopoulos Kleanthis G (President and CEO) Sale 400 7.04 2,816
2014-10-17 Xanthopoulos Kleanthis G (President and CEO) Option Ex 400 .38 152
2014-10-17 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,000 6.79 20,370
2014-10-17 Parshall B Lynne (Director) Sale 3,000 6.79 20,370
2014-10-16 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 4,800 6.76 32,452
2014-10-16 Parshall B Lynne (Director) Sale 4,800 6.76 32,452
2014-10-15 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 4,300 6.67 28,685
2014-10-15 Parshall B Lynne (Director) Sale 4,300 6.67 28,685
2014-10-14 Xanthopoulos Kleanthis G (President and CEO) Sale 400 7.00 2,800
2014-10-14 Xanthopoulos Kleanthis G (President and CEO) Option Ex 400 .38 152
2014-10-10 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,000 6.41 12,812
2014-10-10 Parshall B Lynne (Director) Sale 2,000 6.41 12,812
2014-10-09 Xanthopoulos Kleanthis G (President and CEO) Sale 105 7.00 735
2014-10-09 Xanthopoulos Kleanthis G (President and CEO) Option Ex 105 .38 39
2014-10-09 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 4,750 6.58 31,236
2014-10-09 Parshall B Lynne (Director) Sale 4,750 6.58 31,236
2014-10-08 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,300 6.63 21,888
2014-10-08 Parshall B Lynne (Director) Sale 3,300 6.63 21,888
2014-10-03 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,300 6.88 22,687
2014-10-03 Parshall B Lynne (Director) Sale 3,300 6.88 22,687
2014-10-02 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,750 6.64 24,903
2014-10-02 Parshall B Lynne (Director) Sale 3,750 6.64 24,903
2014-10-01 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,250 6.71 21,807
2014-10-01 Parshall B Lynne (Director) Sale 3,250 6.71 21,807
2014-09-30 Xanthopoulos Kleanthis G (President and CEO) Sale 2,300 7.02 16,136
2014-09-30 Xanthopoulos Kleanthis G (President and CEO) Option Ex 2,300 .38 874
2014-09-26 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,500 7.04 17,597
2014-09-26 Parshall B Lynne (Director) Sale 2,500 7.04 17,597
2014-09-25 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,500 7.12 17,790
2014-09-25 Parshall B Lynne (Director) Sale 2,500 7.12 17,790
2014-09-24 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,750 7.19 26,977
2014-09-24 Parshall B Lynne (Director) Sale 3,750 7.19 26,977
2014-09-19 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 4,100 7.22 29,585
2014-09-19 Parshall B Lynne (Director) Sale 4,100 7.22 29,585
2014-09-18 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,500 7.40 11,097
2014-09-18 Parshall B Lynne (Director) Sale 1,500 7.40 11,097
2014-09-17 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,100 7.43 15,609
2014-09-17 Parshall B Lynne (Director) Sale 2,100 7.43 15,609
2014-09-12 Gibson Neil W (Chief Scientific Officer) Sale 2,200 8.01 17,617
2014-09-12 Gibson Neil W (Chief Scientific Officer) Option Ex 2,200 1.74 3,828
2014-09-12 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,500 7.96 27,860
2014-09-12 Parshall B Lynne (Director) Sale 3,500 7.96 27,860
2014-09-11 Gibson Neil W (Chief Scientific Officer) Sale 2,000 8.01 16,010
2014-09-11 Gibson Neil W (Chief Scientific Officer) Option Ex 2,000 1.74 3,480
2014-09-11 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,400 7.83 26,635
2014-09-11 Parshall B Lynne (Director) Sale 3,400 7.83 26,635
2014-09-10 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,000 7.70 15,400
2014-09-10 Parshall B Lynne (Director) Sale 2,000 7.70 15,400
2014-09-05 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,400 7.07 16,975
2014-09-05 Parshall B Lynne (Director) Sale 2,400 7.07 16,975
2014-09-04 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 6,000 7.11 42,654
2014-09-04 Parshall B Lynne (Director) Sale 6,000 7.11 42,654
2014-09-03 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,650 6.95 11,470
2014-09-03 Parshall B Lynne (Director) Sale 1,650 6.95 11,470
2014-08-29 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,500 6.84 10,254
2014-08-29 Parshall B Lynne (Director) Sale 1,500 6.84 10,254
2014-08-28 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 7.06 24,755
2014-08-28 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2014-08-28 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,000 6.96 13,920
2014-08-28 Parshall B Lynne (Director) Sale 2,000 6.96 13,920
2014-08-27 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,500 7.21 10,821
2014-08-27 Parshall B Lynne (Director) Sale 1,500 7.21 10,821
2014-08-22 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 5,250 6.75 35,442
2014-08-22 Parshall B Lynne (Director) Sale 5,250 6.75 35,442
2014-08-21 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,500 6.89 17,222
2014-08-21 Parshall B Lynne (Director) Sale 2,500 6.89 17,222
2014-08-20 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,000 7.14 21,423
2014-08-20 Parshall B Lynne (Director) Sale 3,000 7.14 21,423
2014-08-15 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,450 6.98 10,115
2014-08-15 Parshall B Lynne (Director) Sale 1,450 6.98 10,115
2014-08-14 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,750 7.04 12,323
2014-08-14 Parshall B Lynne (Director) Sale 1,750 7.04 12,323
2014-08-13 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,250 7.02 15,788
2014-08-13 Parshall B Lynne (Director) Sale 2,250 7.02 15,788
2014-08-08 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,850 6.80 12,581
2014-08-08 Parshall B Lynne (Director) Sale 1,850 6.80 12,581
2014-08-07 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,600 6.66 17,321
2014-08-07 Parshall B Lynne (Director) Sale 2,600 6.66 17,321
2014-08-06 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,150 7.08 22,298
2014-08-06 Parshall B Lynne (Director) Sale 3,150 7.08 22,298
2014-08-05 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 7.06 24,738
2014-08-05 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2014-08-01 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,600 6.21 16,153
2014-08-01 Parshall B Lynne (Director) Sale 2,600 6.21 16,153
2014-07-31 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,750 6.42 11,235
2014-07-31 Parshall B Lynne (Director) Sale 1,750 6.42 11,235
2014-07-30 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,000 6.60 6,602
2014-07-30 Parshall B Lynne (Director) Sale 1,000 6.60 6,602
2014-07-25 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,700 6.55 11,136
2014-07-25 Parshall B Lynne (Director) Sale 1,700 6.55 11,136
2014-07-24 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,850 6.81 12,598
2014-07-24 Parshall B Lynne (Director) Sale 1,850 6.81 12,598
2014-07-23 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,700 6.88 11,702
2014-07-23 Parshall B Lynne (Director) Sale 1,700 6.88 11,702
2014-07-18 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 5,000 6.80 34,000
2014-07-18 Parshall B Lynne (Director) Sale 5,000 6.80 34,000
2014-07-17 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 5,000 6.58 32,905
2014-07-17 Parshall B Lynne (Director) Sale 5,000 6.58 32,905
2014-07-16 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,500 6.59 23,058
2014-07-16 Parshall B Lynne (Director) Sale 3,500 6.59 23,058
2014-07-11 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,750 6.48 11,340
2014-07-11 Parshall B Lynne (Director) Sale 1,750 6.48 11,340
2014-07-10 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 4,500 6.69 30,109
2014-07-10 Parshall B Lynne (Director) Sale 4,500 6.69 30,109
2014-07-09 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,800 7.08 12,747
2014-07-09 Parshall B Lynne (Director) Sale 1,800 7.08 12,747
2014-07-03 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,200 8.06 9,678
2014-07-03 Parshall B Lynne (Director) Sale 1,200 8.06 9,678
2014-07-02 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,100 8.07 25,010
2014-07-02 Parshall B Lynne (Director) Sale 3,100 8.07 25,010
2014-07-01 Gibson Neil W (Chief Scientific Officer) Sale 2,500 8.10 20,259
2014-07-01 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-07-01 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 8.11 28,425
2014-07-01 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2014-06-27 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 3,150 7.92 24,932
2014-06-27 Parshall B Lynne (Director) Sale 3,150 7.92 24,932
2014-06-26 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 1,700 7.89 13,407
2014-06-26 Parshall B Lynne (Director) Sale 1,700 7.89 13,407
2014-06-25 Alnylam Pharmaceuticals, Inc. (10% Owner) Sale 2,750 7.84 21,565
2014-06-25 Parshall B Lynne (Director) Sale 2,750 7.84 21,565
2014-06-17 Gibson Neil W (Chief Scientific Officer) Sale 5,000 8.04 40,225
2014-06-17 Gibson Neil W (Chief Scientific Officer) Option Ex 5,000 1.74 8,700
2014-06-09 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 7.14 25,018
2014-06-09 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2014-05-29 Xanthopoulos Kleanthis G (President & CEO) Sale 887 7.00 6,209
2014-05-29 Xanthopoulos Kleanthis G (President & CEO) Option Ex 887 .38 337
2014-05-28 Xanthopoulos Kleanthis G (President & CEO) Sale 875 7.00 6,125
2014-05-28 Xanthopoulos Kleanthis G (President & CEO) Option Ex 875 .38 332
2014-05-27 Xanthopoulos Kleanthis G (President & CEO) Sale 1,743 7.00 12,202
2014-05-27 Xanthopoulos Kleanthis G (President & CEO) Option Ex 1,743 .38 662
2014-04-09 Gibson Neil W (Chief Scientific Officer) Sale 2,500 8.11 20,272
2014-04-09 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-03-06 Gibson Neil W (Chief Scientific Officer) Sale 2,500 11.37 28,427
2014-03-06 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-03-06 Xanthopoulos Kleanthis G (President & CEO) Sale 7,010 9.47 66,401
2014-03-06 Xanthopoulos Kleanthis G (President & CEO) Option Ex 7,010 .38 2,662
2014-02-06 Gibson Neil W (Chief Scientific Officer) Option Ex 45,000 1.74 78,300
2014-02-05 Gibson Neil W (Chief Scientific Officer) Sale 17,500 8.38 146,702
2014-02-05 Gibson Neil W (Chief Scientific Officer) Option Ex 2,500 1.74 4,350
2014-02-05 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 8.40 29,438
2014-02-05 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2014-02-04 Sanofi (10% Owner) Buy 1,303,780 7.67 9,999,992
2014-01-21 Gibson Neil W (Chief Scientific Officer) Sale 4,421 8.09 35,765
2014-01-21 Gibson Neil W (Chief Scientific Officer) Option Ex 4,421 2.66 11,759
2014-01-17 Gibson Neil W (Chief Scientific Officer) Sale 4,479 8.15 36,494
2014-01-17 Gibson Neil W (Chief Scientific Officer) Option Ex 4,479 2.20 9,853
2014-01-16 Gibson Neil W (Chief Scientific Officer) Sale 1,100 8.03 8,837
2014-01-16 Gibson Neil W (Chief Scientific Officer) Option Ex 1,100 1.74 1,914
2014-01-02 Xanthopoulos Kleanthis G (President & CEO) Sale 3,505 7.25 25,407
2014-01-02 Xanthopoulos Kleanthis G (President & CEO) Option Ex 3,505 .38 1,331
2013-02-04 Gibson Neil W (Chief Scientific Officer) Option Ex 50,000 1.74 87,000
2012-10-10 Parshall B Lynne (Director) Buy 750,000 4.00 3,000,000
2012-10-10 Crooke Stanley T (Director) Buy 750,000 4.00 3,000,000
2012-10-10 Isis Pharmaceuticals Inc (10% Owner) Buy 750,000 4.00 3,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of RGLS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regulus Therapeutics Inc. (symbol RGLS, CIK number 1505512) see the Securities and Exchange Commission (SEC) website.